Clinical Study of 18F-Alfatide Injection PET/CT

Inclusion Criteria: 1. The subjects understand the clinical trial procedure and sign the informed consent in person; 2. Patients with non-small cell lung cancer confirmed or highly suspected by investigators based on prior history, imaging, histopathology, and/or cytology, suspected lymph node metastasis and proposed radical surgery and lymph node dissection; 3. Over 18 years old (including 18 years old); 4. ECOG function status score 0\~1 points ; 5. Expected survival \> 3 months. Exclusion Criteria: 1. Known allergic history to 18F-Alfatide Injection and 18F-FDG injection or its excipients; 2. Patients who cannot tolerate intravenous drug administration (such as needle fainting and blood fainting history); 3. Patients who are not suitable for PET or cannot complete PET or other imaging tests due to special reasons, including claustrophobia and radiophobia; 4. Workers who need to be exposed to radioactive conditions for a long time; 5. Patients with renal insufficiency were defined as the standard endogenous creatinine clearance (Ccr) estimated by the Cockcroft-Gault formula \<60 ml/min, Ccr(ml/min)=\[(140-age)× body weight (kg)\]/\[72×Scr(mg/dl)\], and the calculated result for females was 0.85; 6. Fasting blood glucose level more than 7.0 mmol/L; 7. There are serious infections that cannot be controlled before screening; 8. Any serious disease that cannot be controlled, such as severe heart dysfunction (such as unstable angina pectoris, myocardial infarction, heart failure, etc.), a large number of pleural effusion patients, patients with mental illness, etc.; 9. Previously diagnosed with other malignant tumors, except in the following cases: * Adequately treated basal or squamous cell carcinoma (requiring adequate wound healing prior to enrollment in the study); * Carcinoma in situ of cervical or breast cancer with curative treatment and no signs of recurrence for at least 3 years prior to the study; * The primary malignancy has been completely removed and in complete remission for ≥5 years. 10. Participants who had participated in clinical trials of radiopharmaceuticals within 1 year before screening; 11. Participating in other interventional clinical trials within 1 month before screening; 12. Poor general condition, heart, lung, liver, kidney, brain and other vital organs can not tolerate surgery; 13. Those who had a birth plan during the trial and within 1 year after the completion of the trial, or the subjects and their spouses did not agree to take strict contraceptive measures during the trial and within 6 months after the completion of the trial (using condoms, contraceptive sponges, contraceptive gels, contraceptive membranes, intrauterine devices, oral or injectable contraceptives, subcutaneous implants, etc.); 14. Pregnant or lactating female subjects; 15. Subjects with poor compliance or other factors deemed unsuitable for participation in the study by the investigator.